AREV Life Sciences Global Corp.
AREVF · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $7 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $14 | $14 | $14 | $29 |
| Gross Profit | -$14 | -$14 | -$14 | -$22 |
| % Margin | – | – | – | -299.9% |
| R&D Expenses | $0 | $27 | $0 | $7 |
| G&A Expenses | -$2 | $74 | $146 | -$109 |
| SG&A Expenses | -$2 | $74 | $146 | -$145 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$36 |
| Other Operating Expenses | $30 | $0 | $0 | -$20 |
| Operating Expenses | $28 | $120 | $166 | -$96 |
| Operating Income | -$12 | -$120 | -$166 | $103 |
| % Margin | – | – | – | 1,430.4% |
| Other Income/Exp. Net | -$17 | -$6 | -$10 | -$24 |
| Pre-Tax Income | -$29 | -$121 | -$169 | $80 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$29 | -$121 | -$169 | $80 |
| % Margin | – | – | – | 1,103.9% |
| EPS | -0.001 | -0.004 | -0.005 | 0.003 |
| % Growth | 76.3% | 28.3% | -312% | – |
| EPS Diluted | -0.001 | -0.004 | -0.005 | 0.003 |
| Weighted Avg Shares Out | 31,786 | 31,762 | 31,717 | 31,537 |
| Weighted Avg Shares Out Dil | 31,762 | 31,762 | 31,717 | 31,537 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $14 | $14 | $14 | $29 |
| EBITDA | -$14 | -$106 | -$155 | $110 |
| % Margin | – | – | – | 1,519.8% |